Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide

Hepatitis Monthly

Volumn 12, Issue 10, 2012, Pages

  Zidan, Ahmed ^a   Scheuerlein, Hubert ^a   Schüle, Silke ^a   Settmacher, Utz ^a   Rauchfuss, Falk ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Hepatitis B Virus; Hepatitis C; Iran

Indexed keywords

EID: 84874233501     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6894     Document Type: Review

References (88)

1. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55(4):988-97.
2. Purcell RH. The discovery of the hepatitis viruses. Gastroenterol-ogy. 1993;104(4):955-63.
3. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010;14 (Suppl 3):e113-6.
4. Arababadi MK, Hassanshahi G, Yousefi H. HBV-DNA in hemo-dialysis patients infected by HCV. Saudi J Kidney Dis Transpl. 2009;20(3):398-401.
5. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol. 2007;102(8):1661-70; quiz 0, 71.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6.
7. Yu MC, Yuan JM. Environmental factors and risk for hepatocel-lular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S72-8.
8. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 (Suppl 4):5-13.
9. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-91.
10. International Agency for Research on Cancer. ABOUT CANCER-Mondial. Lyon, France: WHO; 2002; Available from: http://www-dep.iarc.fr.
11. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Com-parability and quality of data. IARC Sci Publ. 1992;(120):45-173.
12. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6.
13. Eftekhari Y, Kazemi Arababadi M, Hakimi H, Rezazadeh Zarandi E. Common HBV genotype in southeastern Iranian patients. Arch Iran Med. 2010;13(2):147-9.
14. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population--a viral marker study. Ann Acad Med Singapore. 1980;9(2):144-8.
15. Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J. 2005;11(1-2):62-7.
16. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2009;14(4):249-58.
17. Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Iran Med. 2000;3:192-201.
18. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med. 2009;12(3):225-31.
19. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol. 2002;17(10):1092-7.
20. Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fara-rouei M. High Prevalence of Hepatitis C Infection among High Risk Groups in Kohgiloyeh and Boyerahmad Province, South-west Iran. Arch Iran Med. 2012;15(5):271-4.
21. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ah-madian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009;86(6):902-8.
22. Zarkesh-Esfahani SH, Kardi MT, Edalati M. Hepatitis C virus geno-type frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J. 2010;7:69.
23. Merat S, Poustchi H. +Hepatitis C in Iran. How extensive of a problem is it? Arch Iran Med. 2012;15(5):268.
24. Erden S, Buyukozturk S, Calangu S, Yilmaz G, Palanduz S, Badur S. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Med Princ Pract. 2003;12(3):184-8.
25. European Centre for Disease Prevention Control. Hepatitis B and C in the EU Neighbourhood: Prevalence, Burden of Disease and Screening Policies: Literature Review. Stockholm: ECDC; 2010
26. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Exami-nation Surveys. J Infect Dis. 1998;178(4):954-9.
27. Chu JJ, Wormann T, Popp J, Patzelt G, Akmatov MK, Kramer A, et al. Changing epidemiology of Hepatitis B and migration--a comparison of six Northern and North-Western European countries. Eur J Public Health. 2012:[Epub ahead of print].
28. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat. 2011;18(Suppl 1):1-16.
29. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82(4):546-55.
30. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26(49):6266-73.
31. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS. 2005;19 (Suppl 3):S41-6.
32. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090-101.
33. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192-201.
34. Chapman LE, Sullivent EE, Grohskopf LA, Beltrami EM, Perz JF, Kretsinger K, et al. Recommendations for postexposure inter-ventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep. 2008;57(RR-6):1-21; quiz CE1-4.
35. From the Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission--United States. JAMA. 1999;281(9):790.
36. From the Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission--United States. JAMA. 1995;274(8):603-4.
37. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine. 2000;18 (Suppl 1):S20-2.
38. Tandon BN, Tandon A. Epidemioplogical trends of viral hepatitis in Asia. Minerva Medica. 1997:559-61.
39. Kew MC. Current epidemiological trends of viral hepatitis in Af-rica. Minerva Medica. 1997:562-6.
40. Al-Faleh FZ, Ayoola EA, Al-Jeffry M, Arif M, Al-Rashed RS, Ramia S. Integration of hepatitis B vaccine into the expanded program on immunization: The Saudi Arabian experience. Ann Saudi Med. 1993;13(3):231-6.
41. Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Im-munol. 2005;194(3):163-8.
42. Abushady EA, Gameel MM, Klena JD, Ahmed SF, Abdel-Wahab KS, Fahmy SM. HBV vaccine efficacy and detection and genotyping of vaccinee asymptomatic breakthrough HBV infection in Egypt. World J Hepatol. 2011;3(6):147-56.
43. El-Raziky MS, El-Hawary MA, Salama KM, El-Hennawy AM, Helmy HM, Fahmy ME, et al. Patterns of hepatitis B infection in Egyptian children in the era of obligatory hepatitis B vaccination. Arab J Gastroenterol. 2012;13(1):1-3.
44. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558-67.
45. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infec-tion. Int J Med Sci. 2006;3(2):41-6.
46. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887-91.
47. World Health Organization. Global database on blood safety summary report. 1998-1999; Available from: http://www.who.int/bloodsafety/global_database/en/.
48. Magder LS, Fix AD, Mikhail NN, Mohamed MK, Abdel-Hamid M, Abdel-Aziz F, et al. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol. 2005;34(1):160-5.
49. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;33(7):1075-107.
50. Tiribelli C, Bellentani S, Campello C. The north-to-south gra-dient of hepatitis C virus infection. Scand J Gastroenterol. 2003;38(8):805-6.
51. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst. 2011;103(22):1686-95.
52. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 (Suppl 3):S206-14.
53. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocel-lular carcinoma. Clin Liver Dis. 2005;9(2):191-211, v.
54. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol. 2000;12(4):357-61.
55. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lan-cet. 2003;362(9399):1907-17.
56. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(5 Suppl 2):S72-8.
57. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY, Lee PH, et al. Silencing of glutathione S-transferase P1 by promoter hypermeth-ylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett. 2005;221(2):135-43.
58. Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol. 2012;18(1):18-22.
59. Radjef N, Gordien E, Ivaniushina V, Gault E, Anais P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004;78(5):2537-44.
60. Taylor JM. Hepatitis delta virus. Virology. 2006;344(1):71-6.
61. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139(10):817-23.
62. (CDC) CfDCaP. Hepatocellular carcinoma-United States, 2001-2006. MMWR Morb Mortal Wkly Rep. 2010;59(17):517-20.
63. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 Suppl 1):S27-34.
64. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14(2):107-15.
65. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562-9.
66. El-Serag HB, Everhart JE. Improved survival after variceal hem-orrhage over an 11-year period in the Department of Veterans Af-fairs. Am J Gastroenterol. 2000;95(12):3566-73.
67. Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis J. 2008;27(10):861-9.
68. Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, et al. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc. 2012;87(1):9-16.
69. Luo RH, Zhao ZX, Zhou XY, Gao ZL, Yao JL. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol. 2005;11(28):4431-4.
70. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362(9401):2089-94.
71. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
72. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24(3):346-53.
73. Wang BE, Ma WM, Sulaiman A, Noer S, Sumoharjo S, Sumarsidi D, et al. Demographic, clinical, and virological characteristics of he-patocellular carcinoma in Asia: survey of 414 patients from four countries. J Med Virol. 2002;67(3):394-400.
74. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res. 2007;37 (Suppl 2):S95-S100.
75. Lehman EM, Soliman AS, Ismail K, Hablas A, Seifeldin IA, Ramadan M, et al. Patterns of hepatocellular carcinoma incidence in Egypt from a population-based cancer registry. Hepatol Res. 2008;38(5):465-73.
76. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004;39(1):211-9.
77. Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. Cancer in the Gam-bia: 1988-97. Br J Cancer. 2001;84(9):1207-14.
78. Umoh NJ, Lesi OA, Mendy M, Bah E, Akano A, Whittle H, et al. Aeti-ological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int. 2011;31(2):215-21.
79. Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AE, Mestiri H, et al. First multicenter study for risk factors for hepatocel-lular carcinoma development in North Africa. World J Hepatol. 2011;3(1):24-30.
80. Triki H. [Epidemiology of hepatitis B virus, hepatitis C virus and Delta virus in the general population and in liver cirrhosis in Tu-nisia]. Arch Inst Pasteur Tunis. 1994;71(3-4):403-6.
81. Kew MC. Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol. 2010;2(2):65-73.
82. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and patho-genesis. World J Gastroenterol. 2008;14(27):4300-8.
83. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J. 2005;26(6):974-7.
84. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM. Burden of he-patocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev. 2010;11(4):859-62.
85. Forbi JC, Vaughan G, Purdy MA, Campo DS, Xia GL, Ganova-Raeva LM, et al. Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria. PLoS One. 2010;5(7):e11615.
86. Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol. 2005;11(26):4085-9.
87. Zakizad M, Salmeh F, Yaghoobi T, Yaghoubian M, Nesami MB, Es-maeeli Z, et al. Seroprevalence of hepatitis C infection and associated risk factors among addicted prisoners in Sari-Iran. Pak J Biol Sci. 2009;12(14):1012-8.
88. Khedmat H, Fallahian F, Abolghasemi H, Alavian SM, Hajibeigi B, Miri SM, et al. Seroepidemiologic study of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and syphilis infections in Iranian blood donors. Pak J Biol Sci. 2007;10(24):4461-6.